知镜 Cognispect · 医学文献与研究工作台

READING SPEED IN MACULAR TELANGIECTASIA TYPE 2: AN ANALYSIS OF SHAM PATIENTS IN THE REVAKINAGENE TARORETCEL-LWEY (NT-501) PHASE 3 TRIALS.

Eliott D, Hatcher KA, Delgiodice MJ, Bitar MI, Yankey J, Sauer L, Chew EY, Aaberg TM.
Retina (Philadelphia, Pa.) · 2026-10-30 · PMID 42961160

文献摘要

Purpose To evaluate the relationship between best-corrected visual acuity (BCVA) and reading speed in the sham-treated cohorts from two Phase 3 clinical trials of revakinagene taroretcel-lwey for macular telangiectasia type 2 (MacTel) and to determine whether reading speed captures functional decline not reflected by changes in BCVA. Methods This secondary analysis evaluated reading speed (words per minute [wpm] per eye using the International Reading Speed Test) and BCVA (Early Treatment Diabetic Retinopathy Study letters) over 24 months. Associations between BCVA loss and reading speed decline were examined using multiple linear regression. Analysis of covariance (ANCOVA) assessed the effect of eye laterality on reading speed, controlling for baseline factors. Results Of 111 enrolled sham-treated eyes, 104 had complete data for analysis. For every 1-letter loss of BCVA, the reading speed decreased by 2.1 wpm (P Conclusion These findings suggest that BCVA may incompletely capture progressive functional vision loss in MacTel, whereas reading speed detected decline even when BCVA remained stable. Given its sensitivity and clinical relevance, reading speed may provide a meaningful endpoint for assessing MacTel progression and therapeutic efficacy and may also help clinicians quantify functional vision loss in routine practice.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。